Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Endoscopy: later-stage trial registry

2 of 8 indexed Endoscopy trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Endoscopy: 8 US clinical trials tracked, 2 recruiting.

Endoscopy is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Braintree Laboratories, running 1 of these trials.

Enrollment posture brief

Registry condition endoscopy

OPEN 2 | RECR 25% | LATE 3 | EARLY 1 | RANK #2176 | SPON 1

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Endoscopy (this)25%
Open-enrollment share among volume-matched conditions near Endoscopy

Endoscopy lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Endoscopy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Endoscopy is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Endoscopy trials is spread across many organizations.

    Braintree Laboratories accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Endoscopy enrolment sits around 229 participants.

    Median target enrolment is 229 among the 8 trials that report a genuine target (sentinel values excluded). 1 of those (12.5%) plan for fewer than 100 participants.

  4. Endoscopy research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 32Phase 41

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Endoscopy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PillCam® COLON 2 procedure using reduced dose of Suprep boosts Other
1 trials
PillCam® COLON 2 procedure using Suprep boosts Other
1 trials
PillCam® COLON 2 procedure using MgC boosts Other
1 trials
Endoscopic clip placement in the gastrointestinal tract. Device
1 trials
BLI800 investigational preparation regimen Drug
1 trials
BLI800 approved preparation regimen Drug
1 trials
PEG-3350 based bowel preparation Drug
1 trials
Standard endoscopic hemostasis Other
1 trials

US sites by state

Facility locations filed on Endoscopy trials. A trial with sites in several states counts in each.

California 4 trials
Massachusetts 3 trials
Indiana 3 trials
Virginia 2 trials
Tennessee 2 trials
Ohio 2 trials
New York 2 trials
North Carolina 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Endoscopy page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endoscopy condition card totals 8 registered trials; most-linked intervention PillCam® COLON 2 procedure using reduced dose of Suprep boosts; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.